TLE4 anticorps (AA 681-773)
-
- Antigène Voir toutes TLE4 Anticorps
- TLE4 (Transducin-like Enhancer Protein 4 (TLE4))
-
Épitope
- AA 681-773
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp TLE4 est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))
- Homologie
- Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse
- Purification
- Purified by Protein A.
- Immunogène
- KLH conjugated synthetic peptide derived from human TLE4
- Isotype
- IgG
- Top Product
- Discover our top product TLE4 Anticorps primaire
-
-
- Indications d'application
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
- Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- TLE4 (Transducin-like Enhancer Protein 4 (TLE4))
- Autre désignation
- TLE4 (TLE4 Produits)
- Synonymes
- anticorps TLE4, anticorps NV17443, anticorps BCE-1, anticorps BCE1, anticorps E(spI), anticorps ESG, anticorps ESG4, anticorps GRG4, anticorps Esp2, anticorps Grg4, anticorps XGrg-4, anticorps XTCF-4, anticorps Xgrg4, anticorps Xtle4, anticorps esg4, anticorps grg4, anticorps gro, anticorps 5730411M05Rik, anticorps AA792082, anticorps Bce-1, anticorps Bce1, anticorps ESTM13, anticorps ESTM14, anticorps X83332, anticorps X83333, anticorps transducin like enhancer of split 4, anticorps transducin-like enhancer protein 4, anticorps protein groucho-1, anticorps transducin-like enhancer of split 4, anticorps transducin like enhancer of split 4-Z 1, anticorps transducin like enhancer of split 4 S homeolog, anticorps TLE4, anticorps LOC706619, anticorps LOC100117159, anticorps LOC100462498, anticorps Tle4, anticorps TLE4Z1, anticorps LOC476317, anticorps tle4.S
- Sujet
-
Synonyms: B lymphocyte gene 1, B lymphocyte gene 1, enhancer of split groucho 4, enhancer of split groucho 4, ESG4, ESG4, KIAA1261, TIM, TIM1, timeless Drosophila homolog, TLE4, transducin-like enhancer of split 4, transducin-like enhancer of split 4, TLE4_HUMAN.
Background: The Notch signaling pathway controls cellular interactions important for the specification of a variety of fates in both invertebrates and vertebrates. Key players in the Notch pathway are the TLE genes (for transducin-like enhancer of split, also designated ESG for enhancer of split groucho), which are human homologs of the Drosophila groucho gene. Groucho is a transcriptional repressor that plays a key role in neurogenesis, segmentation and sex determination. TLEs associate with chromatin in live cells and specifically with Histone H3, but not with other core histones. Expression of the TLE genes, TLE1, TLE2, TLE3 and TLE4, correlate with immature epithelial cells that are progressing toward a terminally differentiated state, suggesting a role during epithelial differentiation. TLE1, TLE2 and TLE3 have elevated expression in cervical squamous metaplasias and carcinomas, while TLE4 is most highly expressed in the brain, particularly in the caudate nucleus. TLE1 and TLE4 contain SP and WD40 domains, through which TLE1 binds AML1 to inhibit AML1-induced transactivation of the CSF1 receptor. In early stages of cell differentiation, TLE1 is upregulated, and TLE2 and TLE4 are downregulated. In later stages, TLE2 and TLE4 are upregulated, and expression of TLE1 decreases.
- ID gène
- 7091
- Pathways
- Signalisation WNT
-